Overview Financials News + Filings Key Docs Charts Holdings Ownership Insiders
|
|
RTI SURGICAL, INC. (RTIX)
|
Add to portfolio |
|
|
|
| Price: |
$3.39
| | Metrics |
| OS: |
62.3
|
M
| |
|
|
| Market cap: |
$211
|
M
| |
-1
|
% ROIC
|
|
Net debt:
|
$38.1
|
M
| |
6.5
|
x Debt/EBITDA
|
|
EV:
|
$249
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
$5.9
|
M
| |
42.2
|
x EV/EBITDA
|
|
EBIT
|
($8.7)
|
M
| |
|
|
| EPS |
$0.07
| |
47.2
|
x P/E
|
|
|
| |
|
|
|
Recent News + Filings (All items)
| Date Filed | Type | Description |
| 07/20/2020 |
GN
| Surgalign Holdings, Inc. (formerly RTI Surgical Holdings, Inc.) Announces Closing of Sale of OEM Business, Name and Ticker Change, and Leadership Transit...
|
| 06/30/2020 |
GN
| Lawsuit for Investors in RTI Surgical Holdings, Inc. (NASDAQ: RTIX) shares announced by Shareholders Foundation |
| 06/30/2020 |
GN
| RTI Surgical Holdings, Inc.® Provides Business Updates |
| 06/24/2020 |
GN
| RTI Surgical Holdings, Inc.® Schedules Business Update Call for June 30, 2020 |
| 06/10/2020 |
GN
| RTI Surgical Holdings, Inc.® Bolsters Spine Business with Key Senior Leadership Appointments |
| 06/08/2020 |
GN
| RTI Surgical Holdings, Inc.® Announces Filing of 2019 10-K and Completion of Financial Statement Restatement |
| 05/26/2020 |
GN
| RTI Surgical Holdings, Inc.® Appoints Stuart F. Simpson to Board of Directors |
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 | Dec-31-11 |
| Revenues | 280.9 | 279.6 | 272.9 | 282.3 | 262.8 | 198.0 | 178.1 | 169.3 |
| Revenue growth | 0.5% | 2.5% | -3.3% | 7.4% | 32.7% | 11.2% | 5.2% | 1.9% |
| Cost of goods sold | 140.7 | 137.0 | 140.5 | 132.6 | 129.0 | 117.9 | 92.9 | 92.1 |
| Gross profit | 140.1 | 142.5 | 132.3 | 149.7 | 133.8 | 80.1 | 85.2 | 77.2 |
| Gross margin | 49.9% | 51.0% | 48.5% | 53.0% | 50.9% | 40.5% | 47.8% | 45.6% |
| Selling, general and administrative | 142.6 | 113.7 | 148.0 | 125.1 | 107.7 | 81.6 | 58.4 | 65.4 |
| Research and development | | | | | 15.5 | 15.2 | 12.2 | |
| EBITA | -4.7 | 26.4 | -15.6 | 26.1 | 10.0 | -15.8 | 14.3 | 13.4 |
| EBITA margin | -1.7% | 9.4% | -5.7% | 9.2% | 3.8% | -8.0% | 8.0% | 7.9% |
| Amortization of intangibles | 4.0 | 3.7 | 3.7 | 4.3 | 4.4 | 3.9 | 2.0 | 2.0 |
| EBIT | -8.7 | 22.6 | -19.2 | 21.8 | 5.6 | -19.8 | 12.2 | 11.4 |
| EBIT margin | -3.1% | 8.1% | -7.1% | 7.7% | 2.1% | -10.0% | 6.9% | 6.8% |
| Pre-tax income | -5.6 | 25.7 | -17.5 | 23.2 | 4.2 | -28.9 | 12.4 | 11.6 |
| Income taxes | -4.3 | 19.5 | -3.1 | 8.3 | 1.5 | -11.1 | 4.0 | 3.2 |
| Tax rate | 77.6% | 75.6% | 17.5% | 35.7% | 35.6% | 38.4% | 32.5% | 27.8% |
| Net income | -1.3 | 6.3 | -14.4 | 0.0 | -0.4 | -19.2 | 8.4 | 0.0 |
| Net margin | -0.4% | 2.2% | -5.3% | 0.0% | -0.2% | -9.7% | 4.7% | 0.0% |
| |
| Diluted EPS | ($0.02) | $0.10 | ($0.25) | $0.00 | ($0.01) | ($0.34) | $0.15 | $0.00 |
| Shares outstanding (diluted) | 63.5 | 60.6 | 58.2 | 58.6 | 56.7 | 56.3 | 56.1 | 55.4 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|